Woodruff: Clinical Research Should Be More Gender-Specific


By Deborah Borfitz

June 16, 2008 | In virtually every medical discipline, there are unanswered questions pertaining to women’s health and well-being. Closing the gender gap in medical research may require more than simply including women in research studies, says Teresa Woodruff, executive director of the Institute for Women’s Health Research, recently launched by Northwestern University’s Feinberg School of Medicine.

“Women experience disease symptoms and respond to therapeutic treatments differently throughout their lifespan and across their monthly menstrual cycle,” says Woodruff. Hormone fluctuations and the possibility of pregnancy among pre-menopausal women have for decades been the rationale for excluding females from medical research. To this day, many researchers prefer using male animals over female animals in their laboratories simply because their hormone environment is less complicated.

 Teresa Woodruff,  Institute for Women's Health, Northwestern University 
Teresa Woodruff
Since the early 1990s, women have been represented as study subjects in higher numbers because the National Institutes of Health, as a condition of funding, now requires that researchers include women in all studies targeting diseases that impact both sexes. However, when male and female trial data gets blended, sex- and gender-specific findings are difficult to evaluate unless the trial was specifically designed to look for sexual dimorphisms, says Woodruff.

Traditionally, women’s health research has focused on issues such as pregnancy, menopause, and female-specific cancers, she adds. Only in the last five years, for example, has the medical community identified sex differences in cardiovascular disease, the leading killer of both men and women. Even far less is known about diagnosing and treating women with diseases of the brain, the musculoskeletal organs, and the immune system. Most reports on adverse drug reactions occur in women because females were not included in many of the early pharmaceutical studies.

Woodruff believes that women want to be a part of the answer. The Institute’s latest project, the Illinois Women’s Health Registry, opened three months ago and has already enrolled over 1,000 Illinois women who are willing to take part in Institutional Review Board-approved research conducted at Northwestern University. Registry participants will be matched to specific studies based on their self-reported health profiles. Woodruff says she hopes the registry “will help us identify priorities that will raise the health status of Illinois women, who now rank 33rd among the states.”

In addition to the registry, the Institute for Women’s Health Research is facilitating more women’s research by offering seed grants to young investigators and by developing an Animal Research Core that will encourage researchers to use female animal models in their studies.

“More physicians are beginning to recognize that sex and gender impact health, but they do not necessarily know the way it relates to age or genetics,” says Woodruff. “That level of sophistication doesn’t exist yet.” But “before we can get to personalized medicine, we need to understand basic sex differences.”

Woodruff predicts, “Ten years from now, the treatment of women and men will be different than it is today because of programs like the Institute for Women’s Health Research.”

________________________________

 This story first appeared in eCliniqua,one of Bio-IT World’s free e-newsletters. Subscribe here.

 

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.